Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells $7,217,142.74 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) insider John Paolini sold 77,587 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $93.02, for a total value of $7,217,142.74. Following the completion of the transaction, the insider directly owned 69,922 shares in the company, valued at approximately $6,504,144.44. This represents a 52.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Down 8.1%

Shares of KNSA stock opened at $88.34 on Friday. Kiniksa Pharmaceuticals International, plc has a 12 month low of $37.02 and a 12 month high of $98.48. The firm has a market cap of $6.89 billion, a PE ratio of 67.95 and a beta of 0.07. The stock has a 50 day moving average of $80.18 and a 200-day moving average of $61.10.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. As a group, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of large investors have recently bought and sold shares of the stock. Curry Webb Wealth Management LLC acquired a new position in Kiniksa Pharmaceuticals International during the third quarter worth $29,000. Allworth Financial LP boosted its stake in shares of Kiniksa Pharmaceuticals International by 42.0% in the 2nd quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after purchasing an additional 134 shares in the last quarter. Nykredit A S acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $34,000. Jacobi Capital Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at $48,000. Finally, KBC Group NV bought a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth about $34,000. 53.95% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on KNSA. Canaccord Genuity Group raised their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. upped their price objective on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a research note on Wednesday, October 28th. Citigroup increased their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.